"10.1371_journal.pone.0117847","plos one","2015-02-17T00:00:00Z","Daniel Rycroft; Jane Sosabowski; Edward Coulstock; Marie Davies; John Morrey; Sarah Friel; Fiona Kelly; Robert Hamatake; Milan Ovečka; Rob Prince; Laura Goodall; Armin Sepp; Adam Walker","Biopharm Innovation Unit, Biopharm Research and Development, GlaxoSmithKline, Cambridge, United Kingdom; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America; Biopharm Translational Medicine, Biopharm R&D, GlaxoSmithKline, Stevenage, United Kingdom; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; Biopharm Discovery, Biopharm R&D, GlaxoSmithKline, Stevenage, United Kingdom","Conceived and designed the experiments: DR JS EC MD JM FK RH AS AW. Performed the experiments: DR JS EC SF FK. Analyzed the data: DR JS EC SF FK JM. Contributed reagents/materials/analysis tools: RP MO LG. Wrote the paper: AW DR MD JM RH.","All authors (except JS and JM) were employees of GlaxoSmithKline at the time this work was carried out. JS is a researcher at Queen Mary University of London, whose work on this project was funded by GlaxoSmithKline. JM is a researcher at Utah State University. All relevant patents have been declared, and there are no products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","02","Daniel Rycroft","DR",13,TRUE,9,5,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
